The SHL Perspective

Empowering Innovation

SHL's Molly® is an autoinjector designed to address various fill volumes of complex biologics. Built upon a preconfigured technology, Molly® aims to support shortened development timelines for pharmaceutical companies.

Feb 5-6 Paris, France Booth C64

Learn more at 2020 Pharmapack Europe

Molly® 2.25 is a large volume variation of the Molly® autoinjector, enabling it to accommodate the high volume requirement of complex biologics. With an upgrade in industrial design that is optimized for production, the new Molly® is designed to meet the evolving requirements of future autoinjectors such as scalable manufacturing.

The Molly® autoinjector supports fill volumes in the 1-2.25 mL range, enabling it to accommodate various volume requirements of complex biologics. Molly® is easy-to-use with its two-step operation, and is designed with a flange-shaped cap to prevent unwanted rolling.

Molly® 2.25

Molly® is an incredibly intuitive and easy-to-use autoinjector built with a preconfigured technology developed to minimize customer investments and speed up development timelines.

Bigger Volume

Close

Built for higher volume injections, Molly® 2.25 supports the trends for injection volumes in the 1-2.25mL range. This allows new drugs to be delivered in autoinjector and launched products to be dosed less frequently.

Better Grip

Close

Deepened ridges on Molly®’s cap enhances grip. Its flange-shaped top facilitates cap removal, and its rectangular contour prevents unwanted rolling to ance the device’s safety.

Easier Handling

Close

As a preconfigured offering, Molly® 2.25 is designed to be easily understood and accepted by a variety of patient groups. Having inherited the classic Molly®’s 2-step process, Molly® 2.25 is as compact, intuitive and easy to use.

Faster Timelines

Close

SHL’s final assembly, labeling and packaging services were established to create added value for our partners following the successful design and development of their device, resulting in a fully integrated service from device design to commercialization.

Preconfigured Technology

Close

A high-volume variation of SHL's classic Molly® autoinjector, Molly® 2.25 is a preconfigured device that can also support various levels of customization to meet client specifications. 

Preconfigured Technology

A high-volume variation of SHL's classic Molly® autoinjector, Molly® 2.25 is a preconfigured device that can also

support various levels of customization

to meet client specifications. 

Easier Handling

As a preconfigured offering, Molly® 2.25 is designed to be easily understood and accepted by a variety of patient groups. Having inherited the classic Molly®’s 2-step process, Molly® 2.25 is as compact, intuitive and easy to use.

Refined Design

Deepened ridges on Molly®’s cap enhances grip. Its flange-shaped top facilitates cap removal, and its rectangular contour prevents unwanted rolling to enhance the device’s safety.

Bigger Volume

Built for higher volume injections, Molly® 2.25 supports the trends for injection volumes in the 1-2.25mL range. This allows new drugs to be delivered in autoinjector and launched products to be dosed less frequently.

Faster Timelines

SHL’s final assembly, labeling and packaging services were established to create added value for our partners following the successful design and development of their device, resulting in a fully integrated service from device design to commercialization.

Molly® 2.25 is a large volume variation of the Molly® autoinjector, enabling it to accommodate the high volume requirement of complex biologics. With an upgrade in industrial design that is optimized for production, the new Molly® is designed to meet the evolving requirements of future autoinjectors such as scalable manufacturing.

The Molly® autoinjector supports fill volumes in the 1-2.25 mL range, enabling it to accommodate various volume requirements of complex biologics. Molly® is easy-to-use with its two-step operation, and is designed with a flange-shaped cap to prevent unwanted rolling.

Go to article: Home | A cure for a costGo to article: In this issueGo to article: SHL Group Company InsightGo to article: Scandinavian HealthGo to article: ContentsGo to article: NewsGo to article: NSFGo to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Covid-19 executive briefing by GlobalDataGo to article: The value of real-world evidence during the Covid-19 outbreakGo to article: Covid-19: UK restricts parallel export of nearly 200 drugs, threatening its biopharma industryGo to article: Pharmaceutical professionals say employee safety and supply chain disruption are top Covid-19 concernsGo to article: AbbVie’s, Ascletis’ protease inhibitors spark skeptical outlook for repurposed activity in Covid-19Go to article: PhoenixGo to article: Phoenix Company InsightGo to article: The pharma industry briefingGo to article: No time to waste: repurposing drugs to tackle covid-19Go to article: How safe are simple painkillers?Go to article: Molnar Company Insight Go to article: Molnar-InstituteGo to article: Modelling the human body: a game changer for drug testing?Go to article: Pandemic pricing: existing drugs and price gougingGo to article: Contract Pharmaceuticals Limited CanadaGo to article: Pandemic pricing: novel treatments and vaccinesGo to article: The dark side of anticoagulants: will a new approach shed light?Go to article: Zenatek Go to article: Finding a cure for HIV with ViiV Healthcare and UNC-Chapel HillGo to article: Disputing the facts: is the legal battle between Veeva and IQVIA an antitrust issueGo to article: Nelson LabsGo to article: Could nanoparticles unlock the pharmaceutical benefits of turmeric?Go to article: Why aren’t more companies automating PV data capture?Go to article: Modality SolutionsGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: ButterworthGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: MimotopesGo to article: EventsGo to article: Next issue